Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 13;39(9):1178-1180.
doi: 10.1016/j.ccell.2021.07.017. Epub 2021 Aug 12.

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

Xiuning Le  1 , Monique B Nilsson  1 , Jacqulyne P Robichaux  1 , John V Heymach  2
Affiliations
Comment

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

Xiuning Le et al. Cancer Cell. .

Abstract

The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests John Heymach receives consulting and/or advisory fees from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation Medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche, and Leads Biolabs, and he receives research funding from AstraZeneca, GlaxoSmithKline, and Spectrum. John Heymach receives royalties and licensing fees from Spectrum. John Heymach, Jacqulyne Robichaux, and Monique Nilsson have a pending patent submitted for treatment of EGFR tyrosine kinase resistant NSCLC. John Heymach and Jacqulyne Robichaux have another pending patent submitted for the classification of EGFR mutations. Monique Nilsson has filed a patent for the use of poziotinib for treating EGFR and HER2 mutant cancers. She has licensed the technology to Spectrum Pharmaceuticals, and she receives royalties and licensing fees. Jacqulyne Robichaux receives research support from Spectrum Pharmaceuticals and Takeda and has filed a patent for the use of poziotinib for treating EGFR and HER2 mutant cancers. She has licensed the technology to Spectrum Pharmaceuticals, and she receives royalties and licensing fees. Xiuning Le receives consulting and/or advisory fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim, and Bristol-Myers Squibb, and research funding from Eli Lilly, EMD Serono, Regeneron, and Boehringer Ingelheim.

Comment on

MeSH terms

LinkOut - more resources